Open AccessCapecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer
Author(s) -
Bala Basak Oven Ustaalioğlu,
Ahmet Bılıcı,
Metin Tilki,
Ali Sürmelioğlu,
Burçak Erkol,
Metin Figen,
Serab Uyar
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.183548
Subject(s) - medicine , capecitabine , regimen , fluorouracil , radiation therapy , chemoradiotherapy , oncology , tolerability , lymph node , surgery , cisplatin , adjuvant therapy , chemotherapy , gastroenterology , cancer , adverse effect , colorectal cancer
Although surgery is considered to be curative treatment, recurrence rates are high in gastric cancer. Adjuvant 5-fluorouracil (5-FU) based chemoradiotherapy has been shown to improve the prognosis. We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer.